NASDAQ Listing Done, Oculis Eyes Phase III Readouts
Decent Cash Position After SPAC Merger
Having taken the special purpose acquisition corporation route to list in the US, Switzerland's Oculis is waiting for some vital late-stage data, notably on OCS-01 for diabetic macular edema.
You may also be interested in...
Oculis has enjoyed a strong first six months of 2023 after demonstrating the potential of OCS-01 to treat a variety of eye conditions and establishing a presence in the US.
The Swiss firm’s lead candidate has hit the mark in the first stage of a pivotal diabetic macular edema program, edging closer to becoming the first eye drop treatment for a condition where unmet need remains despite the advent of anti-VEGFs.
Aesther Healthcare Acquisition extended the deadline to merge with Ocean Biomedical, while Intrinsic Medicine no longer plans to go public by merging with a SPAC. In restructuring news, Otonomy begins liquidation, Celyad cuts last clinical program with cash running out and Clovis files for bankruptcy.